CLOs on the Move

Q2 Solutions

www.q2labsolutions.com

 
Q² Solutions, a Quintiles Quest joint venture Launched in 2015, Q² Solutions (pronounced Q-squared) is a leading global clinical trials laboratory services organization. We help biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q² Solutions is a quality driven, responsive partner with strong global experience and deep scientific and medical expertise. The Q² Solutions joint venture was formed by Quintiles and Quest Diagnostics, combining the best of each parent organizations clinical trials laboratory services capabilities.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

HealthServe Medical Group

HealthServe is a progressive organization designed to infuse our clients with the technology and services that will enable them to flourish in today's demanding business environment. Our broad range of experience is organized into three dynamic service

Sanara MedTech

With our focus on improving patient outcomes with evidence-based healing solutions, we develop, market and distribute biotechnology products to physicians, hospitals, clinics and all post-acute care settings. We are constantly seeking long-term partnerships with a focus on products that produce efficacious outcomes at a lower overall cost. Our products are primarily sold in the North American surgical tissue repair and advanced wound care markets.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.

Pacific Health Systems

Pacific Health Systems is a National City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.